Lorazepam dose-dependently decreases risk-taking related activation in limbic areas
Lorazepam dose-dependently decreases risk-taking related activation in limbic areas
复制标题
DOI：
10.1007/s00213-006-0519-8
复制
发表时间：
2006-11-01
影响因子：
3.4
通讯作者：
Paulus, Martin P.
中科院分区：
文献类型：
--
作者：
Arce, Estibaliz;Miller, Daniel A.;Paulus, Martin P.
基本原理 几项研究探讨了不同神经递质系统在调节冒险行为中的作用。 目的 本研究旨在确定苯二氮卓类劳拉西泮是否剂量依赖性地改变冒险行为和潜在的神经底物。 材料和方法 15 名健康、不吸烟的个体（6 名女性，9 名男性），年龄 18-39 岁（平均 27.6 +/- 1.4 岁），受过 12-18 年教育（平均 15.6 +/- 0.3 岁）在执行冒险决策任务时接受了功能性磁共振成像。 结果 我们的结果表明，劳拉西泮在 0.25 和 1 mg 剂量下不会影响危险行为，但在反应选择阶段 (a) 杏仁核和内侧前额叶皮层以及 (b) 结果期间双侧岛叶皮层和杏仁核的激活呈剂量依赖性减弱（即奖励或惩罚）阶段。此外，劳拉西泮诱导的岛叶皮质激活增加与风险较小的反应相关。 结论 综上所述，我们的研究结果支持这样的观点：边缘和旁边缘结构中的 GABA 能调节在冒险决策的反应选择和结果阶段都很重要。
Rationale Several studies have examined the role of different neurotransmitter systems in modulating risk-taking behavior.Objective This investigation was aimed to determine whether the benzodiazepine lorazepam dose-dependently alters risk-taking behavior and underlying neural substrates.Materials and methods Fifteen healthy, nonsmoking, individuals ( six women, nine men), aged 18-39 years ( mean 27.6 +/- 1.4 years) with 12-18 years of education (mean 15.6 +/- 0.3 years) underwent functional magnetic resonance imaging while performing a risk-taking decision- making task.Results Our results show that lorazepam did not affect risky behavior at 0.25 and 1 mg, but dose-dependently attenuated activation in (a) the amygdala and medial prefrontal cortex during the response selection phase, and in (b) the bilateral insular cortex and amygdala during the outcome (i.e., rewarded or punished) phase. Furthermore, a lorazepam-induced increase in insular cortex activation was associated with less risky responses.Conclusions Taken together, our findings support the idea that GABAergic modulation in limbic and paralimbic structures is important during both the response selection and outcome phase of risk-taking decision-making.